Name
GS02-01 - Randomized phase 3 study of datopotamab deruxtecan vs chemotherapy for patients with inoperable or metastatic hormone receptor-positive, HER2- breast cancer: efficacy, safety and biomarker results from TROPION-Breast01.
Date & Time
Thursday, December 7, 2023
Speakers
Virtual Session Link
OnDemand Video URL